Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Jacobio Pharmaceuticals Group Co., Ltd. ( (HK:1167) ).
Jacobio Pharmaceuticals announced its interim results for the first half of 2025, highlighting significant progress in its drug pipeline. Key achievements include the market approval of glecirasib for NSCLC patients with KRAS G12C mutations, and promising results from trials involving sitneprotafib and other investigational drugs. The company is advancing its clinical trials in China and the U.S., with ongoing studies in multiple cancer types, including a pivotal Phase II basket study. These developments underscore Jacobio’s commitment to expanding its oncology portfolio and enhancing its market position.
The most recent analyst rating on (HK:1167) stock is a Hold with a HK$5.30 price target. To see the full list of analyst forecasts on Jacobio Pharmaceuticals Group Co., Ltd. stock, see the HK:1167 Stock Forecast page.
More about Jacobio Pharmaceuticals Group Co., Ltd.
Jacobio Pharmaceuticals Group Co., Ltd. is a pharmaceutical company focused on the development of innovative cancer therapies. The company specializes in targeted therapies for various cancer types, leveraging its expertise in drug discovery and development to address unmet medical needs in oncology.
Average Trading Volume: 7,710,745
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.87B
Learn more about 1167 stock on TipRanks’ Stock Analysis page.